Literature DB >> 3412321

Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.

C M Lin1, S B Singh, P S Chu, R O Dempcy, J M Schmidt, G R Pettit, E Hamel.   

Abstract

Combretastatin, an antineoplastic and antimitotic agent, was isolated from the bark of Combretum caffrum [Can. J. Chem. 60: 1374-1376 (1982); Biochem. Pharmacol. 32:3864-3867 (1983)]. Structurally, combretastatin consists of two substituted benzene rings linked by a saturated, hydroxy-substituted two-carbon bridge. A large number of combretastatin analogs have now been synthesized or obtained from C. caffrum. These vary in substituents on the phenyl rings or bridge carbons, bridge length, unsaturation of the bridge (i.e., stilbene derivatives, with the two phenyl rings oriented either cis or trans), and in precise ring structure (two major variants, with the bridge incorporated into a third six-member ring to form a phenanthrene structure or a methyl group eliminated from vicinal methoxy substituents to form a benzodioxole ring). Available analogs (17 natural products and 22 synthetic agents) were examined for antimitotic and cytotoxic activity and for effects on tubulin polymerization and colchicine binding. Nineteen compounds inhibited cell growth by 50% or more at concentrations of 1 microM or less, and 14 inhibited tubulin polymerization by at least 50% at stoichiometric drug concentrations. The most potent cytotoxic agents generally strongly inhibited both tubulin polymerization and the binding of colchicine to tubulin. The most promising compound is the (cis)-stilbene derivative (cis)-1-(3,4,5-trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl)ethene, which has been named combretastatin A-4. This compound inhibited cell growth by 50% at 7 nM, inhibited tubulin polymerization by 50% at 2.5 microM (1/4 molar equivalent), and competitively inhibited colchicine binding with an apparent Ki of 0.14 microM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3412321

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum.

Authors:  Jiabo Wang; Zhijie Ma; Ming Niu; Yun Zhu; Qingsheng Liang; Yanling Zhao; Jingyuan Song; Zhaofang Bai; Yaming Zhang; Ping Zhang; Na Li; Yakun Meng; Qi Li; Lushan Qin; Guangju Teng; Junling Cao; Baosen Li; Shilin Chen; Yonggang Li; Zhengsheng Zou; Honghao Zhou; Xiaohe Xiao
Journal:  Front Med       Date:  2015-10-12       Impact factor: 4.592

2.  Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

Authors:  Mikhail Krasavin; Andrey V Sosnov; Ruben Karapetian; Igor Konstantinov; Olga Soldatkina; Elena Godovykh; Fedor Zubkov; Ruoli Bai; Ernest Hamel; Andrei A Gakh
Journal:  Bioorg Med Chem Lett       Date:  2014-08-08       Impact factor: 2.823

3.  Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.

Authors:  D Christopher Meadows; Tino Sanchez; Nouri Neamati; Thomas W North; Jacquelyn Gervay-Hague
Journal:  Bioorg Med Chem       Date:  2006-10-30       Impact factor: 3.641

4.  Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.

Authors:  Kyoko Nakagawa-Goto; Pei-Chi Wu; Chin-Yu Lai; Ernest Hamel; Hao Zhu; Liying Zhang; Takashi Kozaka; Emika Ohkoshi; Masuo Goto; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2011-02-01       Impact factor: 7.446

5.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

6.  Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy.

Authors:  Tomohiro Doura; Kazuaki Takahashi; Yasumitsu Ogra; Noriyuki Suzuki
Journal:  ACS Med Chem Lett       Date:  2017-01-20       Impact factor: 4.345

7.  Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.

Authors:  Lauren Lee; Lyda M Robb; Megan Lee; Ryan Davis; Hilary Mackay; Sameer Chavda; Balaji Babu; Erin L O'Brien; April L Risinger; Susan L Mooberry; Moses Lee
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

8.  Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum.

Authors:  Chunyu Li; Ming Niu; Zhaofang Bai; Congen Zhang; Yanling Zhao; Ruiyu Li; Can Tu; Huifang Li; Jing Jing; Yakun Meng; Zhijie Ma; Wuwen Feng; Jinfa Tang; Yun Zhu; Jinjie Li; Xiaoya Shang; Zhengsheng Zou; Xiaohe Xiao; Jiabo Wang
Journal:  Front Med       Date:  2017-03-17       Impact factor: 4.592

Review 9.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Authors:  Dietmar W Siemann; David J Chaplin; Patricia A Walicke
Journal:  Expert Opin Investig Drugs       Date:  2009-02       Impact factor: 6.206

10.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.

Authors:  R J D'Amato; C M Lin; E Flynn; J Folkman; E Hamel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.